Source - LSE Non-Regulatory
RNS Number : 5137D
Creo Medical Group PLC
22 June 2023
 

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Appointment of Marco Scarci to lead Pulmonary Clinical Advisory Group  

Group to help shape and take forward Creo's MicroBlate™ clinical strategy

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that it has appointed Marco Scarci as lead of the Company's newly created Pulmonary Clinical Advisory Group.

 

Marco Scarci, who will provide expert clinical advice and counsel in relation to the Company's microwave ablation technology, is a highly experienced London-based Consultant Thoracic Surgeon, specialising in minimally invasive techniques. His specialist training took place in Italy, Malta, the Essex Cardiothoracic Centre and Guy's and St Thomas', London. Following a six-month fellowship in minimally invasive surgery at the University of Toronto, Canada, Mr Scarci was appointed Consultant Thoracic Surgeon at Papworth Hospital NHS Foundation Trust, Cambridge.  

 

Marco joins Creo as it looks to develop and build on clinical trials to assess the safe and effective ablation of pre-cancerous and cancerous lesions through the Company's MicroBlate™ products. Marco's extensive network will enable him to engage with Kamaptive partners, medical advisors, key opinion leaders and medical societies to help shape and take forward Creo's microwave ablation clinical strategy, with a view to maximising the impact the technology can have on patients around the world.

 

Marco Scarci said of his appointment: "I'm delighted to join Creo Medical and to help shape an ablation clinical strategy with the aim of demonstrating what I and many others believe this technology to be - a potential game changer in the way soft tissue lesions can be treated in future."

 

Craig Gulliford, Chief Executive Officer of Creo Medical, added "We welcome Marco's vast clinical experience to the team. With one clinical trial for our lung ablation technology already under way and further trials in the pipeline, it's fantastic to have such a globally respected mind helping guide us as we look to maximise the impact of our technology and achieve the best possible outcomes for patients across multiple indications."

 

 

Enquiries:

 

Creo Medical Group plc

www.creomedical.com

Richard Rees (CFO)

+44 (0)1291 606 005



Cenkos Securities plc

+44 (0)20 7397 8900

Stephen Keys / Camilla Hume (NOMAD)


Michael Johnson / Russell Kerr (Joint Broker)




Numis Securities Limited (Joint Broker)

+44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Euan Brown




Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com

Paul McManus / Sam Allen 

/ Phillip Marriage 

Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 

About Creo Medical 

 

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions.  CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRADGGDLDGDDGXB
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Creo Medical Group PLC (CREO)

-0.50p (-1.47%)
delayed 16:30PM